Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 68, Issue 8, 2009, Pages 1328-1333

  Trocme C ^a,b   Marotte, H ^c   Baillet, A ^a   Pallot Prades, B ^d   Garin, J ^e   Grange, L ^a   Miossec, P ^c   Tebib, J ^f   Berger, F ^b   Nissen, M J ^a   Juvin, R ^a   Morel, F ^a,b   Gaudin, P ^a  

^a LABORATOIRE TIMC IMAG   (France)

^b HÔPITAL MICHALLON   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d SERVICE DE NEUROLOGIE   (France)

^e CEA GRENOBLE   (France)

^f CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM SULFATE; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; INFLIXIMAB; METAL; NICKEL; THROMBOCYTE FACTOR 4; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AFFINITY CHROMATOGRAPHY; AGED; ANION EXCHANGE; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; PROTEOMICS; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; STRONG ANION EXCHANGE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; APOLIPOPROTEIN A-I; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET FACTOR 4; PROGNOSIS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TREATMENT OUTCOME;

EID: 67651230876     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.093153     Document Type: Article

References (41)

1. Roux CH, Saraux A, Le Bihan E, Fardellone P, Guggenbuhl P, Fautrel B, et al. Rheumatoid arthritis and spondyloarthropathies: geographical variations in prevalence in France. J Rheumatol 2007;34:117-22.
2. Molenaar ETH, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BAC. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004;50:36-42.
3. Le Loet X, Berthelot JM, Cantagrel A, Combe B, De Bandt M, Fautrel B, et al. Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology. Ann Rheum Dis 2006;65:45-50.
4. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46;328-46.
5. Kievit W, Fransen J, Oerlemans AJ, Kuper HH, van de Laar MA, de Rooij DR, et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomized controlled trials and clinical practice. Ann Rheum Dis 2007;66:1473-8.
6. Garnero P, Landewe R, Boers M, Verhoeven A, van der Linden S, Christgau S, et al. Association of baseline levels of markers of bone and cartilage degradation with longterm progression of joint damage in patients with early rheumatoid arthritis. Arthritis Rheum 2002;46:2847-56.
7. Morel J, Combe B. How to predict prognosis in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2005;19:137-46.
8. Seibert V, Wiesner A, Buschmann T, Meuer J. Surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI TOF-MS) and ProteinChipH technology in proteomics research. Pathol Res Pract 2004;200:83-94.
9. Vorderwulbecke S, Cleverley S, Weinberger SR, Wiesner A. Protein quantification by the SELDI-TOF-MS-based ProteinChipH system. Nat Methods 2005;2:393-5.
10. Hodgetts A, Levin M, Kroll JS, Langford PR. Biomarker discovery in infectious diseases using SELDI. Future Microbiol 2007;2:35-49.
11. Davidsson P, Sjögren M. Proteome studies of CSF in AD patients. Mech Ageing Dev 2006;127:133-7.
12. Vanhoutte KJ, Laarakkers C, Marchiori E, Pickkers P, Wetzels JF, Willems JL, et al. Biomarker discovery with SELDI-TOF MS in human urine associated with early renal injury: evaluation with computational analytical tools. Nephrol Dial Transplant 2007;22:2932-43.
13. Zhang Z, Bast RC, Yu Y, Li J, Sokoll LJ, Rai AJ, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64:5882-90.
14. Clarke CH, Buckley JA, Fung ET. SELDI-TOF-MS proteomics of breast cancer. Clin Chem Lab Med 2005;43:1314-20.
15. Mueller J, von Eggeling F, Driesch D, Schubert J, Melle C, Junker K. ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients. Eur Urol 2005;47:885-93.
16. Seibert V, Ebert MP, Buschmann T. Advances in clinical cancer proteomics: SELDITOF-mass spectrometry and biomarker discovery. Brief Funct Genomic Proteomic 2005;4:16-26.
17. Uchida T, Fukawa A, Uchida M, Fujita K, Saito K. Application of a novel protein biochip technology for detection and identification of rheumatoid arthritis biomarkers in synovial fluid. J Proteome Res 2002;1:495-9.
18. De Seny D, Fillet M, Meuwis MA, Geurts P, Lutteri L, Ribbens C, et al. Discovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry proteinchip approach. Arthritis Rheum 2005;52:3801-12.
19. Marotte H, Pallot-Prades B, Grange L, Tebib J, Gaudin P, Alexandre C, et al. The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. Ann Rheum Dis 2006;65:342-7.
20. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 1976;72:248-54.
21. Breiman L, Freidman JH, Olshen RA, Stone CJ. Classification and regression trees. New York, USA: Chapman and Hall, 1984.
22. Vermeulen R, Lan Q, Zhang L, Gunn L, McCarthy D, Woodbury RL, et al. Decreased levels of CXC-chemokines in serum of benzene-exposed workers identified by arraybased proteomics. Proc Natl Acad Sci USA 2005;102:17041-6.
23. Lam YW, Mobley JA, Evans JE, Carmody JF, Ho SM. Mass profiling-directed isolation and identification of a stage-specific serologic protein biomarker of advanced prostate cancer. Proteomics 2005;5:2927-38.
24. Lakatos J; Harsagyi A. Serum total, HDL, LDL cholesterol, and triglyceride levels in patients with rheumatoid arthritis. Clin Biochem 1988;21:93-6.
25. Doherty NS, Littman BH, Reilly K, Swindell AC, Buss JM, Anderson NL. Analysis of changes in acute-phase plasma proteins in an acute inflammatory response and in rheumatoid arthritis unsing two-dimensional gel electrophoresis. Electrophoresis 1998;19:355-63.
26. Park YB, Lee SK, Lee WK, Suh CH, Lee CW, Lee CH, et al. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 1999;26:1701-4.
27. Park YB, Choi HK, Kim MY, Lee WK, Song J, Kim DK, et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 2002;113:188- 93.
28. Dayer JM. The saga of discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis. Joint Bone Spine 2002;69:123-32.
29. Bresnihan B, Gogarty M, Fitzgerald O, Dayer JM, Burger D. Apolipoprotein A-I infiltration in rheumatoid arthritis synovial tissue: a control mechanism of cytokine production ? Arthritis Res Ther 2004;6:R563-6.
30. Ananth L, Prete PE, Kashyap ML. Apolipoproteins A-I and B and cholesterol in synovial fluid of patients with rheumatoid arthritis. Metab Clin Exp 1993;42:803-6.
31. Hyka N, Dayer JM, Modoux C, Kohno T, Edwards CK, Roux-Lombard P, et al. Apolipoprotein A-I inhibits the production of interleukin-1β and tumor necrosis factor-α by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 2001;97:2381-9.
32. Burger D, Dayer JM. High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation ? Autoimmun Rev 2002;1:111-7.
33. Chenaud C, Merlani PG, Roux-Lombard P, Burger D, Harbarth S, Luyasu S, et al. Low apolipoprotein A-I level at intensive care unit admission and systemic inflammatory response syndrome exacerbation. Crit Care Med 2004;32:632-7.
34. Van Halm VP, Nielen MMJ, Nurmohamed MT, van Schaardenburg D, Reesink HW, Voskuyl AE, et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007;66:184-8.
35. Slunggard A. Platelet factor 4: a chemokine enigma. Int J Biochem Cell Biol 2005;37:1162-7.
36. Endresen GK. Evidence for activation of platelets in the synovial fluid from patients with rheumatoid arthritis. Rheumatol Int 1989;9:19-24.
37. Erdem H, Pay S, Musabak U, Simsek I, Dinc A, Pekel A, et al. Synovial angiostatic non-ELR CXC chemokines in inflammatory arthritides: does CXCL4 designate chronicity or synovitis ? Rheumtol Int 2007;27:969-73.
38. Yamamoto T, Chikungo T, Tanaka Y. Elevated plasma levels of β-thromboglobulin and platelet factor 4 in patients with rheumatoid disorders and cutaneous vasculitis. Clin Rheumatol 2002;21:501-4.
39. Meuwis MA, Fillet M, Lutteri L, Marée R, Geurts P, de Seny D, et al. Proteomics for prediction and characterization of response to infliximab in Crohn disease: a pilot study. Clin Biochem 2008;41:960-7.
40. Kasper B, Brandt E, Bulfone-Paus S, Petersen F. Platelet factor 4 (PF-4)-induced neutrophil adhesion is controlled by src-kinases, whereas PF-4-mediated exocytosis requires the additional activation of p38 MAP kinase and phosphatidyl 3-kinase. Blood 2004;103:1602-10.
41. Scheuerer B, Ernst M, Dürrbaum-Landmann I, Fleischer J, Grage-Griebenow E, Brandt E, et al. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Blood 2000;95:1158-66.